United Kingdom (UK)
Recombinant monoclonal antibody to IGF1R. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma IGFR 24-55.
UniProt Accession Number of Target Protein: P08069
Alternative Name(s) of Target: CD221; IGF1 receptor; Insulin-like growth factor 1 receptor; type I IGF receptor; Insulin-like growth factor I receptor; IGF-I receptor; 24 55
Immunogen: This antibody was raised by immunising BALB/c mice with transfected mouse fibroblasts expressing high levels of human IGF1R (IGF1R/3T3).
Specificity: This antibody is specific for the human insulin-like growth factor 1 receptor (IGF1R). It recognises the extracellular portion of the receptor, specifically an epitope in the alpha subunit (amino acids 440-514). It does not cross-react with rat or mouse IGF1R or human insulin receptors in co-precipitation or immunodepletion assays.
Application Notes: The ability of this antibody to bind human IGF1R has been confirmed in IGF1 binding assays using both IG1FR-overexpressing IGF1R/3T3 cells and soluble receptors (Soos et al, 1992). This antibody efficiently precipitates IGF1R from lysates of IGF1R-transfected cells (Kavran et al, 2014; Soos et al, 1992), as well as receptor-IGF1 complexes (Soos et al, 1992). When immobilised, this antibody has been shown to remove essentially all soluble IGF1R in immunodepletion experiments (Soos et al, 1992).This antibody weakly inhibits IGF1 binding to its receptor (Soos et al, 1993).
Antibody first published in:
Soos et al. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. 1992 Jun 25;267(18):12955-63. PMID:1377676
Note on publication:
Describes the original generation of this antibody, and the characterisation of its specificity.